Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Rating of “Buy” by Analysts

Soleno Therapeutics, Inc. (NASDAQ:SLNO) has been given an average rating of “Buy” by the fifteen research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $111.4615.

SLNO has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Wednesday, October 8th. Wolfe Research initiated coverage on shares of Soleno Therapeutics in a research report on Tuesday, November 18th. They set an “outperform” rating and a $75.00 target price for the company. The Goldman Sachs Group set a $125.00 price target on shares of Soleno Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Wells Fargo & Company reiterated an “overweight” rating and issued a $106.00 price objective (down previously from $123.00) on shares of Soleno Therapeutics in a research note on Wednesday, November 5th. Finally, Wall Street Zen raised Soleno Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th.

Institutional Investors Weigh In On Soleno Therapeutics

Large investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in Soleno Therapeutics in the 2nd quarter valued at about $25,000. Danske Bank A S purchased a new position in shares of Soleno Therapeutics in the third quarter worth about $27,000. Nisa Investment Advisors LLC raised its position in shares of Soleno Therapeutics by 287.8% in the second quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock valued at $45,000 after purchasing an additional 400 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in shares of Soleno Therapeutics in the third quarter valued at approximately $37,000. Finally, Quarry LP purchased a new stake in shares of Soleno Therapeutics during the 3rd quarter valued at approximately $47,000. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Price Performance

Shares of NASDAQ SLNO opened at $46.29 on Wednesday. The company has a market capitalization of $2.49 billion, a PE ratio of -25.16 and a beta of -3.15. The company has a quick ratio of 15.88, a current ratio of 16.08 and a debt-to-equity ratio of 0.10. The stock’s 50 day moving average price is $52.20 and its 200-day moving average price is $65.90. Soleno Therapeutics has a twelve month low of $41.50 and a twelve month high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.39. The business had revenue of $66.02 million for the quarter, compared to analysts’ expectations of $47.46 million. On average, equities analysts anticipate that Soleno Therapeutics will post -3.72 EPS for the current year.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.